Key result
A novel homozygous nonsense mutation (W464X) in the LMF1 gene was identified in a patient with severe hypertriglyceridemia, resulting in a 76% reduction in LPL activity and 50% reduction in LPL mass.
Case Report (n=1)
The identification of a novel homozygous nonsense mutation (W464X) in the LMF1 gene expands the known genetic etiologies of severe hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
LMF1 sequencing may identify rare causes of unexplained severe hypertriglyceridemia; leaves open prevalence and clinical utility pending validation.
CONTEXT: Lipase maturation factor 1 (LMF1) gene is a novel candidate gene in severe hypertriglyceridemia. Lmf1 is involved in the maturation of lipoprotein lipase (LPL) and hepatic lipase in endoplasmic reticulum. To date only one patient with severe hypertriglyceridemia and related disorders was found to be homozygous for a nonsense mutation in LMF1 gene (Y439X). OBJECTIVE: The objective of the study was to investigate LMF1 gene in hypertriglyceridemic patients in whom mutations in LPL, APOC2, and APOA5 genes had been excluded. RESULTS: The resequencing of LMF1 gene led to the discovery of a novel homozygous nonsense mutation in one patient with severe hypertriglyceridemia and recurrent episodes of pancreatitis. The mutation causes a G>A substitution in exon 9 (c.1395G>A), leading to a premature stop codon (W464X). LPL activity and mass were reduced by 76 and 50%, respectively, compared with normolipidemic controls. The proband over the years has shown a good response to treatment. The proband's son, heterozygous for the W464X, shows normal plasma triglyceride levels. CONCLUSIONS: We identified the second novel pathogenic mutation in LMF1 gene in a patient with severe hypertriglyceridemia. LPL deficiency in our patient was milder than in the carrier of the Y439X previously described.
No takes yet. Share an insight, caveat, or question.
Cefalù et al. (2009) conducted a case report in Severe hypertriglyceridemia (n=1). LMF1 gene nonsense mutation (W464X) vs. Normolipidemic controls was evaluated on LPL activity and mass. A novel homozygous nonsense mutation (W464X) in the LMF1 gene was identified in a patient with severe hypertriglyceridemia, resulting in a 76% reduction in LPL activity and 50% reduction in LPL mass.
Synapse has enriched 10 related papers. Consider them for comparative context: